Mechanism of diepoxybutane-induced p53 regulation in human cells

Journal of Biochemical and Molecular Toxicology

Volumn 23, Issue 6, 2009, Pages 373-386

  Yadavilli, Sridevi ^a,d   Chen, Zhenping ^b   Albrecht, Thomas ^b   Muganda, Perpetua M ^a,c  

^a SOUTHERN UNIVERSITY   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c NORTH CAROLINA A AND T STATE UNIVERSITY   (United States)

^d PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Butadiene; Diepoxybutane; HEL human fibroblasts; p53; TK6 human lymphoblasts

Indexed keywords

ATM PROTEIN; BUTADIENE DIEPOXIDE; LYSINE; PROTEIN MDM2; PROTEIN P53; SERINE;

ACETYLATION; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; EMBRYO; EXPOSURE; FETUS LUNG; FIBROBLAST; HUMAN; HUMAN CELL; LYMPHOBLAST; PROTEIN DEFICIENCY; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REGULATORY MECHANISM; TOXICITY;

ACETYLATION; CELL CYCLE PROTEINS; CELL LINE; DNA-BINDING PROTEINS; EPOXY COMPOUNDS; HUMANS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

ATAXIA TELANGIECTASIA;

EID: 74749096363     PISSN: 10956670     EISSN: 10990461     Source Type: Journal    
DOI: 10.1002/jbt.20300     Document Type: Article

References (73)

1. National Toxicology Program. Ninth Report on Carcinogens. Research Triangle Park, NC: U.S. Department of Health and Human Services; 2000.
2. U.S. Environmental Protection Agency. Health Assessment of 1,3-Butadiene: Office of Research and Development, National Center for Environmental Assessment; 2002. 66151-66152.
3. Doerr JK, Hollis EA, Sipes IG. Species difference in the ovarian toxicity of 1,3-butadiene epoxides in B6C3F1 mice and Sprague-Dawley rats. Toxicology 1996;113(1-3):128-136.
4. Melnick RL, Sills RC. Comparative carcinogenicity of 1,3-butadiene, isoprene, and chloroprene in rats and mice. Chem Biol Interact 2001;135-136:27-42.
5. National Toxicology Program. NTP Toxicology and Carcinogenesis Studies of 1,3-Butadiene (CAS No. 106-99-0) in B6C3F1 Mice (Inhalation Studies): National Toxicol. Program Tech. Rep. Ser; 1993 May 1993. 1-389.
6. Penn A, Snyder CA. 1,3-Butadiene exposure and cardiovascular disease. Mutat Res 2007;621(1-2):42-49.
7. Bond JA, Medinsky MA. Insights into the toxicokinetics and toxicodynamics of 1,3-butadiene. Chem Biol Interact 2001;135-136:599-614.
8. Kligerman AD, Hu Y. Some insights into the mode of action of butadiene by examining the genotoxicity of its metabolites. Chem Biol Interact 2007;166(1-3):132-139.
9. Murg M, Schuler M, Eastmond DA. Evaluation of micronuclei and chromosomal breakage in the 1cen-q12 region by the butadiene metabolites epoxybutene and diepoxybutane in cultured human lymphocytes. Mutagenesis 1999;14(6):541-546.
10. Recio L, Steen AM, Pluta LJ, Meyer KG, Saranko CJ. Mutational spectrum of 1,3-butadiene and metabolites 1,2-epoxybutene and 1,2,3,4-diepoxybutane to assess mutagenic mechanisms. Chem Biol Interact 2001;135-136:325-341.
11. Fred C, Tornqvist M, Granath F. Evaluation of cancer tests of 1,3-butadiene using internal dose, genotoxic potency, and a multiplicative risk model. Cancer Res 2008;68(19):8014-8021.
12. Vodicka P, Stetina R, Smerak P, Vodickova L, Naccarati A, Barta I,Hemminki K. Micronuclei, DNA single-strand breaks and DNA-repair activity in mice exposed to 1,3-butadiene by inhalation. Mutat Res 2006;608(1):49-57.
13. Hurst HE. Toxicology of 1,3-butadiene, chloroprene, and isoprene. Rev Environ Contam Toxicol 2007;189:131-179.
14. Swenberg JA, Boysen G, Georgieva N, Bird MG, Lewis RJ. Future directions in butadiene risk assessment and the role of cross-species internal dosimetry. Chem Biol Interact 2007;166(1-3):78-83.
15. Erexson GL, Tindall KR. Reduction of diepoxybutane-induced sister chromatid exchanges by glutathione peroxidase and erythrocytes in transgenic Big Blue mouse and rat fibroblasts. Mutat Res 2000;447(2):267-274.
16. Erexson GL, Tindall KR. Micronuclei and gene mutations in transgenic big Blue((R)) mouse and rat fibroblasts after exposure to the epoxide metabolites of 1,3-butadiene. Mutat Res 2000;472(1-2):105-117.
17. Steen AM, Meyer KG, Recio L. Analysis of HPRT mutations occurring in human TK6 lymphoblastoid cells following exposure to 1,2,3,4-diepoxybutane. Mutagenesis 1997;12(2):61-67.
18. Irons RD, Pyatt DW, Stillman WS, Som DB, Claffey DJ, Ruth JA. Comparative toxicity of known and putative metabolites of 1, 3-butadiene in human CD34(+) bone marrow cells. Toxicology 2000;150(1-3):99-106.
19. Yadavilli S, Muganda PM. Diepoxybutane induces caspase and p53-mediated apoptosis in human lymphoblasts. Toxicol Appl Pharmacol 2004;195(2):154-165.
20. Lahav G. Oscillations by the p53-Mdm2 feedback loop. Adv Exp Med Biol 2008;641:28-38.
21. Oren M. Decision making by p53: life, death, cancer. Cell Death Differ. 2003;10(4):431-442.
22. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008;7(12):979-987.
23. Viadiu H. Molecular architecture of tumor suppressor p53. Curr Top Med Chem 2008;8(15):1327-1334.
24. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - the p53 network. J Cell Sci 2003;116(Pt 20):4077-4085.
25. Hofseth LJ, Robles AI, Yang Q, Wang XW, Hussain SP, Harris C. p53: at the crossroads of molecular carcinogenesis and molecular epidemiology. Chest 2004;125(5 Suppl):83S-85S.
26. Meulmeester E, Jochemsen AG. p53: a guide to apoptosis. Curr Cancer Drug Targets 2008;8(2):87-97.
27. Scoumanne A, Chen X. Protein methylation: a new mechanism of p53 tumor suppressor regulation. Histol Histopathol 2008;23(9):1143-1149.
28. Kuribayashi K, El-Deiry WS. Regulation of programmed cell death by the p53 pathway. Adv Exp Med Biol 2008;615:201-221.
29. Shen Y, White E. p53-Dependent apoptosis pathways. Adv Cancer Res 2001;82:55-84.
30. Murray-Zmijewski F, Slee EA, Lu X. A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol 2008;9(9):702-712.
31. Reisman D, Boggs K. Transcriptional regulation of the p53 tumor suppressor gene: a potential target for cancer therapeutics? Recent Pat DNA Gene Seq 2007;1(3):176-185.
32. Fu L, Benchimol S. Participation of the human p53 3'UTR in translational repression and activation following gamma-irradiation. Embo J 1997;16(13):4117-4125.
33. Halaby MJ, Yang DQ. p53 Translational control: a new facet of p53 regulation and its implication for tumorigenesis and cancer therapeutics. Gene 2007;395(1-2):1-7.
34. Takagi M, Absalon MJ, McLure KG, Kastan MB. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 2005;123(1):49-63.
35. Zhang J, Chen X. Posttranscriptional regulation of p53 and its targets by RNA-binding proteins. Curr Mol Med 2008;8(8):845-849.
36. Naski N, Gajjar M, Bourougaa K, Malbert-Colas L, Fahraeus R, Candeias MM. The p53 mRNA-Mdm2 interaction. Cell Cycle 2009;8(1):31-34.
37. Bassett EA, Wang W, Rastinejad F, El-Deiry WS. Structural and functional basis for therapeutic modulation of p53 signaling. Clin Cancer Res 2008;14(20):6376-6386.
38. Staples OD, Steele RJ, Lain S. p53 as a therapeutic target. Surgeon 2008;6(4):240-243.
39. Schmiederer M, Knutson E, Muganda P, Albrecht T. Acute exposure of human lung cells to 1,3-butadiene diepoxide results in G1 and G2 cell cycle arrest. Environ Mol Mutagen 2005;45(4):354-364.
40. Sjoblom T, West A, Lahdetie J. Apoptotic response of spermatogenic cells to the germ cell mutagens etoposide, adriamycin, and diepoxybutane. Environ Mol Mutagen 1998;31(2):133-148.
41. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998;281(5383):1674-1677.
42. Nakagawa K, Taya Y, Tamai K, Yamaizumi M. Requirement of ATM in phosphorylation of the human p53 protein at serine 15 following DNA double-strand breaks. Mol Cell Biol 1999;19(4):2828-2834.
43. Dey A, Verma CS, Lane DP. Updates on p53: modulation of p53 degradation as a therapeutic approach. Br J Cancer 2008;98(1):4-8.
44. Moll UM, Petrenko O. The mdm2-p53 interaction. Mol Cancer Res 2003;1(14):1001-1008.
45. Lin T,Mak NK, Yang MS. MAPK regulate p53-dependent cell death induced by benzo[a]pyrene: involvement of p53 phosphorylation and acetylation. Toxicology 2008;247(2-03):145-153.
46. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 1998;12(18):2831-2841.
47. Appella E, Anderson CW. Signaling to p53: breaking the posttranslational modification code. Pathol Biol (Paris) 2000;48(3):227-245.
48. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001;268(10):2764-2772.
49. Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ 2006;13(6):941-950.
50. Borges HL, Chao C, Xu Y, Linden R, Wang JY. Radiation-induced apoptosis in developing mouse retina exhibits dose-dependent requirement for ATM phosphorylation of p53. Cell Death Differ 2004;11(5):494-502.
51. Komiyama S, Taniguchi S, Matsumoto Y, Tsunoda E, Ohto T, Suzuki Y, Yin HL, Tomita M, Enomoto A, Morita A, Suzuki T, Ohtomo K, Hosoi Y, Suzuki N. Potentiality of DNA-dependent protein kinase to phosphorylate Ser46 of human p53. Biochem Biophys Res Commun 2004;323(3):816-822.
52. Kurz EU, Douglas P, Lees-Miller SP. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J Biol Chem 2004;279(51):53272-53281.
53. Lavin MF, Delia D, Chessa L. ATM and the DNA damage response. Workshop on ataxia-telangiectasia and related syndromes. EMBO Rep 2006;7(2):154-160.
54. Siu WY, Lau A, Arooz T, Chow JP, Ho HT, Poon RY. Topoisomerase poisons differentially activate DNA damage checkpoints through ataxia-telangiectasia mutated-dependent and -independent mechanisms. Mol Cancer Ther 2004;3(5):621-632.
55. Meek DW. The p53 response to DNA damage. DNA Repair (Amsterdam) 2004;3(8-9):1049-1056.
56. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387(6630):299-303.
57. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by mdm2. Cell 1997;91(3):325-334.
58. Brune B, Schneiderhan N. Nitric oxide evoked p53-accumulation and apoptosis. Toxicol Lett 2003;139(2-3):119-123.
59. Schneiderhan N, Budde A, Zhang Y, Brune B. Nitric oxide induces phosphorylation of p53 and impairs nuclear export. Oncogene 2003;22(19):2857- 2868.
60. Blattner C. Regulation of p53: the next generation. Cell Cycle 2008;7(20):3149-3153.
61. Boehme KA, Kulikov R, Blattner C. p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK. Proc Natl Acad Sci USA 2008;105(22):7785- 7790.
62. Wang S, Shi X. Mechanisms of Cr(VI)-induced p53 activation: the role of phosphorylation, mdm2 and ERK. Carcinogenesis 2001;22(5):757-762.
63. Kruse JP, Gu W. SnapShot: p53 posttranslational modifi-cations. Cell 2008;133(5):930-930 e1.
64. Xu Y. Regulation of p53 responses by post-translational modifications. Cell Death Differ 2003;10(4):400-403.
65. Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R, Brady JN. Phosphorylation of p53 serine 15 increases interaction with CBP. J Biol Chem 1998;273(49):33048-33053.
66. Bean LJ, Stark GR. Phosphorylation of serines 15 and 37 is necessary for efficient accumulation of p53 following irradiation with UV. Oncogene 2001;20(9):1076-1084.
67. Saito S, Goodarzi AA, Higashimoto Y, Noda Y, Lees-Miller SP, Appella E, Anderson CW. ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J Biol Chem 2002;277(15):12491- 12494.
68. Saito S, Yamaguchi H, Higashimoto Y, Chao C, Xu Y, Fornace AJ, Jr., Appella E, Anderson CW. Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem 2003;278(39):37536-37544.
69. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004;4(10):793-805.
70. Bean LJ, Stark GR. Regulation of the accumulation and function of p53 by phosphorylation of two residues within the domain that binds to Mdm2. J Biol Chem 2002;277(3):1864-1871.
71. Joubel A, Chalkley RJ, Medzihradszky KF, Hondermarck H, Burlingame A. Identification of new p53 acetylation sites inCos-1 cells.Mol Cell Proteomics 2009 (Epub ahead of print).
72. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell 2008;133(4):612-626.
73. Yadavilli S, Martinez-Ceballos E, Snowden-Aikens J, Hurst A, Joseph T, Albrecht T, Muganda PM. Diepoxybutane activates the mitochondrial apoptotic pathway and mediates apoptosis in human lymphoblasts through oxidative stress. Toxicol In Vitro 2007;21(8):1429-1441.